查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827421

中樞神經系統藥物市場按藥物類別、劑型、患者類型、作用機制、治療領域、通路、製劑類型和銷售模式分類－2025-2032 年全球預測

Central Nervous System Drugs Market by Drug Class, Dosage Form, Patient Type, Mechanism Of Action, Therapeutic Area, Distribution Channel, Prescription Type, Sales Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，中樞神經系統藥物市場將成長至 494.6 億美元，複合年成長率為 10.38%。

主要市場統計數據
基準年2024年 224.4億美元
預計2025年 248億美元
預測年份：2032年 494.6億美元
複合年成長率（%） 10.38%

簡述不斷發展的中樞神經系統治療格局，重點在於臨床創新、病患需求和商業化促進因素

由於科學進步的不斷融合、監管預期的不斷變化以及醫療服務模式的不斷變化，中樞神經系統治療領域正處於關鍵的十字路口。本執行摘要說明定義現代中樞神經系統治療開發和商業化的廣泛治療層級、劑型、患者群體、作用機制和通路。透過闡明這些要素如何相互作用，讀者可以更好地理解臨床創新如何滿足未滿足的需求，以及哪些營運或政策限制需要主動緩解。

從止痛藥和抗憂鬱症到抗癲癇藥和抗精神病藥，開發策略越來越重視精準性、耐受性和長期安全性。新的製劑和給藥技術旨在提高依從性並減少全身副作用，而數位醫療輔助工具則將自身定位為症狀追蹤和行為干預的補充解決方案。同時，付款人的期望和真實世界證據要求提高了證明相對有效性和價值的標準，從而影響了臨床開發計劃和商業化時間表。

中樞神經系統領域需要涵蓋科學機制、病患細分和管道動態的綜合觀點。本介紹將為深入分析重塑該領域的結構性變化、改變成本和供應考慮的政策變化，以及為目標產品和市場策略提供參考的細分洞察奠定基礎。

神經科學、給藥技術和護理模式的進步如何重塑中樞神經系統藥物的開發、獲取和生命週期策略

中樞神經系統領域的變革性轉變是由科學、技術和醫療保健體系的融合趨勢所驅動的。分子神經科學的進步以及對突觸和神經傳導物質路徑理解的不斷加深，正在催生新的治療靶點，推動新類別的在臨床實驗藥物的研發和現有療法機制的改進。精準醫療方法植根於生物標記開發和分層試驗設計，使得針對不同疾病狀態的干涉措施更具針對性，並由此重塑臨床開發策略和監管參與。

與科學創新同步，給藥科學和製劑工程正在改變患者的用藥途徑。緩釋性平台、新型經皮系統和緩釋腸外劑型正成為優先發展方向，以提高患者依從性，並在競爭激烈的治療類別中實現產品差異化。數位化療法和依從性工具正日益融入藥物研發項目，以展示以患者為中心的療效並支持報銷談判。這些互補工具也為超越生命週期管理和傳統藥品銷售的全新收益模式創造了機會。

不斷發展的醫療保健體係正在重新定義商業化管道。不斷擴展的遠距醫療、遠端監控和基於藥房的藥物遞送模式正在改變患者獲取中樞神經系統藥物的方式以及臨床醫生管理長期疾病的方式。同時，法律規範和付款方對真實世界證據的要求促使製造商在研發早期就規劃核准後的證據產生。這些轉變的共同作用正在創造一種新格局：科學新穎性、交付創新和證據生成必須協調一致，才能實現商業性和臨床的成功。

了解美國關稅變化對中樞神經系統治療供應鏈彈性、製造選擇和通路經濟的多方面影響

近期源自美國的關稅政策正在對中樞神經系統治療藥物的供應鏈、製造經濟效益和戰略採購決策施加多方面壓力。依賴海外供應商原料藥、輔料和成品的公司必須重新評估其供應商組合，並提高對分層供應關係的可視性，以維持供應的連續性。此類調整通常會提升地理多元化和雙重採購安排的重要性，以吸收政策帶來的成本和物流衝擊。

關稅主導的成本上漲將對中樞神經系統價值鏈的不同環節產生不同的影響。雖然提供差異化療法的創新公司可能更有能力協商價格調整或透過價值爭議吸收邊際成本上漲，但低利潤類別的學名藥製造商將面臨最佳化生產效率和確保低成本原料的壓力。考慮將某些製造活動轉移到國內或擴大區域產能已成為產品組合規劃討論的常規內容，尤其對於需要複雜製造能力的劑型，例如緩釋性口服固體製劑和特種注射劑。

為了因應與關稅相關的干擾，商業團隊也正在審視其分銷策略。通路經濟的變化可能會影響醫院藥房、零售藥房網路和線上藥房夥伴關係之間的平衡決策。此外，監管和付款方格局可能會透過影響報銷動態和採購政策，進一步加劇關稅的影響。這將更重視情境規劃、明確與供應商的合約保護以及加強供應鏈管治，以保障醫療保健的連續性和商業性可行性。

基於藥品類別、劑型、患者群、機制、治療領域、通路、處方狀態和銷售模式的細分，提供深入洞察，實現精準的策略調整

詳細的細分視圖揭示了跨產品、患者、機制、治療領域、通路、處方狀態和銷售模式維度的差異化商業機會和營運重點。依藥品類別，有鎮痛藥、抗憂鬱症、抗癲癇藥、抗精神病藥、抗焦慮藥、中樞神經系統興奮劑和鎮靜安眠藥等類別。鎮痛藥類別進一步分為非鴉片類鎮痛藥和鴉片類鎮痛藥，每種鎮痛藥都有不同的臨床考慮和監管審查。抗癲癇藥物依作用機轉分為鈣通道阻斷劑、GABA 增效劑、麩胺酸抑制劑和鈉通道阻斷劑，有助於臨床前建模和臨床終點選擇。抗精神病藥物分為非典型和典型，抗焦慮藥物分為苯二氮平類和非苯二氮平類。興奮劑的特徵是安非他命和哌甲酯變體，而鎮靜催眠藥則包括巴比妥類藥物、苯二氮平類藥物和非苯二氮平類催眠藥。了解這些類別的差異對於臨床定位和監管風險評估至關重要。

劑型類別包括膠囊、注射、口服錠、錠劑和經皮貼片。膠囊可以是標準緩釋性，而注射劑可以是肌肉注射、靜脈注射或皮下注射，每種途徑都有各自的臨床用例和供應鏈影響。口服製劑通常以混懸液或糖漿的形式提供，而藥片則配製成延遲釋放、緩釋型或標準即時釋型。經皮吸收貼片被設計為基質或儲存系統，是提高某些適應症的依從性和穩態暴露的重要途徑。這些劑量特性會影響開發的複雜性、監管提交、製造投資和商業性訊息。

病患類型細分可識別成人、老年和兒童病患群體，強調適合年齡的配方、給藥策略和安全監測的必要性。作用機制細分突出了膽鹼能、多巴胺能、GABA 能、麩胺酸、去甲腎上腺素能和血清素能方法，為生物標記選擇和治療方法差異化提供了框架。治療領域細分包括注意力不足過動症 (ADHD)、阿茲海默症、焦慮、憂鬱症、癲癇、失眠、偏頭痛、疼痛、帕金森氏症和思覺失調症。每個領域都有不同的終點、合併症概況和相關人員的期望，這些都會影響臨床開發和上市路徑。分銷通路細分（醫院、線上和零售）會影響履約策略、病患援助計畫和報銷安排。處方藥類型細分區分非處方藥 (OTC) 和處方藥，從而影響監管分類和消費者行銷。銷售模式細分區分品牌學名藥，並決定促銷力度、定價彈性和生命週期延長策略。這些細分共同構成一個矩陣，幫助決策者根據病患和市場需求調整研發重點、製造投資和商業性策略。

亞太地區、歐洲、中東和非洲的區域策略各不相同，確定監管策略、製造地和市場進入路線

區域動態對臨床重點、監管參與、生產策略和商業性執行有重大影響。美洲市場環境受付款人主導的結果預期、成熟的臨床試驗生態系統以及有利於證明真實世界有效性的複雜報銷結構的影響。臨床開發往往強調比較療效終點和長期安全性數據，而商業策略通常側重於管理式醫療談判以確保處方藥覆蓋、與專業藥房合作以及與醫生網路互動。

歐洲、中東和非洲的監管多樣性和各自不同的採購體系，導致准入考量呈現錯綜複雜的局面。這一廣大區域內的國家實施不同程度的集中評估和分散採購，要求製造商提供差異化的市場進入文件，以適應各國的醫療技術評估 (HTA) 流程和本地價格談判。此外，與區域製造地和製造外包建立策略夥伴關係關係有助於管理市場准入和跨境供應鏈風險。臨床開發計劃通常會在早期納入跨司法管轄區的要求，以簡化核准和報銷流程。

亞太地區臨床試驗活動強勁成長，生物製造投資不斷增加，數位醫療應用日益普及。當地監管機構正在加強能力建設，簡化創新療法的批准流程，各國政府也正在投資建設關鍵療法的國內生產能力。分銷通路創新，尤其是線上藥局模式和遠端醫療服務的快速擴張，正在塑造慢性中樞神經系統疾病的可近性。這些區域特徵要求我們根據當地支付者、處方者和患者的行為，客製化製造地決策、監管參與順序和商業模式。

創新者、專業生物技術公司、學名藥和製造合作夥伴為在中樞神經系統治療領域獲得競爭優勢而採用的策略策略和協作方法

主要企業展現出多樣化的策略態勢，反映了其產品線成熟度、商業組合組成和營運優勢。創新者強調差異化的作用機制和新穎的給藥平台，以建立臨床差異化，同時投資真實世界證據計畫和病患支持服務，以驗證其價值提案。特種生技公司通常專注於狹窄的適應症，且有大量未滿足的需求，並可能尋求合作和許可，以加速後期開發和商業化。

學名藥和契約製造正專注於規模化、成本最佳化和靈活的生產能力，以滿足對成熟製劑類型的需求，並支援快速填充和完成生產。這些公司也正在探索複雜緩釋性和經皮系統的生產機會，以贏得更高價值的生產合約。在治療學和技術創新的交匯點，數位健康公司和平台提供者正在與製藥公司合作，將依從性追蹤、遠端監控和療效評估整合到產品價值鏈中，從而促進支持報銷對話的新證據生成途徑。

無論產品類型如何，有效的策略包括與學術中心和臨床網路進行有針對性的合作，以接觸特定患者群體；與監管機構及早溝通，明確證據預期；以及進行嚴格的生命週期管理，透過配方改進和產品說明書擴展來提升產品相關性。將研發重點與切合實際的商業性執行計劃和強大的供應鏈管治相結合的公司，將最有能力應對中樞神經系統市場的複雜局面。

領導者應採取切實的策略措施，加強供應鏈韌性，使製劑創新與付款人證據保持一致，並加速中樞神經系統療法的上市

產業領導者應制定一系列切實可行的優先事項，在科學抱負與營運及市場現實之間取得平衡。首先，透過多元化供應商關係，並採用關鍵活性成分和複雜輔料的雙重採購，增強供應鏈的韌性。基於情境的採購計畫和合約保護措施可以減輕政策中斷的影響，並降低病患服務中斷的風險。

其次，策略性地投資於符合依從性和安全性要求的劑型創新。緩釋性、經皮系統和患者友善口服溶液可以使產品在競爭類別中脫穎而出，並支持改善臨床療效。產品團隊必須將這些製劑選擇與付款人證據需求以及可控制複雜性和上市時間的現實生產路徑結合。

第三，從一開始就設計整合真實世界證據產生的開發項目。及早規劃實用性試驗、基於註冊庫的結果收集以及核准後安全性研究，可以加速報銷討論並強化臨床價值主張。第四，優先制定有打入市場策略，透過及早與付款人和衛生技術評估機構溝通，了解證據閾值，並共同設計對覆蓋決策至關重要的結果指標。

第五，我們將尋求與整個生態系統的夥伴關係——包括學術中心、數位醫療公司和經驗豐富的合約研究機構——合作，以填補能力缺口並加快產品上市速度。最後，我們將實施差異化的商業策略，根據患者細分和醫療服務提供者的工作流程客製化通訊和管道組合，在適當情況下利用專業藥房的能力，並採用線上藥局管道來滿足不斷變化的患者偏好。

結合主要專家訪談、系統性二次綜合和情境主導分析的調查方法概述，確保對中樞神經系統市場提供可重複且可操作的見解

本分析背後的調查方法將結構化的一手資料研究與全面的二次綜合相結合，從而得出穩健的三角關聯洞察。一手資料研究包括對參與中樞神經系統藥物研發和分銷的臨床專家、監管專家、供應鏈經理以及商業領袖的深入訪談。這些訪談提供了關於臨床重點、證據預期和營運限制的定性背景資訊，為戰略決策提供參考。

我們的二次研究包括對同行評審文獻、臨床試驗註冊庫、監管指南、上市公司資訊揭露和行業會議資料的系統性回顧。數據在多個公共和資訊來源資訊來源之間進行交叉檢驗，以減少偏差並確保解讀的一致性。我們也整合了近期產品上市和監管互動的案例分析，以揭示跨治療層級和劑型的實用經驗。

分析方法包括主題綜合以識別跨領域趨勢，情境規劃以探索政策和供應鏈變化的影響，以及差距分析以發現未滿足的臨床和商業性需求。品管包括專家同行評審和透過迭代檢驗解決分歧。調查方法強調透明度、可重複性和可操作性的解讀，確保研究結果可直接應用於投資組合規劃、實質審查和打入市場策略。

整合以綜合臨床差異化、營運彈性和付款人一致證據生成為重點的策略要務，以確保持續的中樞神經系統市場准入

當從科學進步、製劑創新、監管演變和分銷轉型中獲得的洞見相結合時，一個核心主題浮現：在中樞神經系統（CNS）治療領域取得成功，需要整合策略。能夠將機制新穎性轉化為患者相關療效，同時確保供應連續性和付款人一致性的公司將創造永續的價值。相反，低估現代付款人和醫療保健提供者的營運和證據生成需求的公司，儘管臨床前景光明，但仍可能面臨准入障礙。

清晰的策略規劃植根於細分市場主導的規劃、區域差異以及對供應鏈和政策動態的深入理解，使相關人員能夠優先考慮投資並設計夥伴關係加速臨床和商業里程碑的實現。本摘要中的建議旨在指南周到的行動，以加強供應鏈、提高依從性、選擇差異化產品的配方和交付模式、儘早與付款人和監管機構溝通，並將真實世界證據納入商業化計劃。採用這些實踐將有助於團隊應對中樞神經系統 (CNS) 市場的複雜性，並定位新型和成熟療法，以實現持續的臨床和商業性影響力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用人工智慧整合數位療法進行個人化憂鬱症管理的人數正在增加
  • FDA核准新型神經保護藥物，減緩阿茲海默症進展
  • 擴大以迷幻藥為基礎的難治性精神疾病治療方法新藥研發管線
  • 增加對精準醫療生物標記的投資，以預測癲癇治療的有效性
  • 用於思覺失調症抗精神病藥物傳遞的長效植入裝置的出現
  • 加強生物技術與學術界的合作，加速中樞神經系統藥物的發現與開發
  • 整合真實世界數據和穿戴式裝置以監測多發性硬化症的治療結果

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 中樞神經系統藥物市場（依藥物類別）

  • 止痛藥
    • 非鴉片類止痛藥
    • 鴉片類止痛藥
  • 抗憂鬱症
  • 抗癲癇藥物
    • 鈣離子通道阻斷劑
    • GABA增強劑
    • 麩胺酸抑制劑
    • 鈉通道阻斷劑
  • 抗精神病藥物
    • 非典型
    • 固定形式
  • 抗焦慮藥物
    • 苯二氮平類藥物
    • 非苯二氮平類藥物
  • 中樞神經興奮劑
    • 安非他命
    • 哌甲酯
  • 催眠鎮靜劑
    • 巴比妥類藥物
    • 苯二氮平類藥物
    • 非苯二氮平類催眠藥

9. 中樞神經系統藥物市場（按劑型）

  • 膠囊
    • 緩釋性膠囊
    • 標準膠囊
  • 注射液
    • IM
    • IV
    • 皮下
  • 口服溶液
    • 暫停
    • 糖漿
  • 藥片
    • 延遲釋放片
    • 緩釋片
    • 標準平板電腦
  • 經皮吸收貼片
    • 矩陣補丁
    • 水庫斑塊

第 10 章：中樞神經系統藥物市場（依病患類型）

  • 成人
  • 老年人
  • 孩子們

第 11 章：中樞神經系統藥物市場（依作用機轉）

  • 膽鹼能
  • 多巴胺能
  • GABA能
  • 麩胺酸
  • 去甲腎上腺素能
  • 血清素能

12. 中樞神經系統藥物市場（依治療領域）

  • ADHD
  • 阿茲海默症
  • 焦慮
  • 憂鬱症
  • 癲癇
  • 失眠
  • 偏頭痛
  • 疼痛
  • 帕金森氏症
  • 思覺失調症

13. 中樞神經系統藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 14 章中樞神經系統藥物市場（按劑型）

  • OTC
  • 處方箋

第 15 章中樞神經系統藥物市場（依銷售模式）

  • 品牌
  • 非專利的

16. 中樞神經系統藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 17 章：中樞神經系統藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 18 章：各國中樞神經系統藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭態勢

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Roche Holding AG
    • Biogen Inc.
    • Novartis AG
    • Johnson & Johnson
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Teva Pharmaceutical Industries Ltd.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • Sanofi SA
Product Code: MRR-434CCDA05199

The Central Nervous System Drugs Market is projected to grow by USD 49.46 billion at a CAGR of 10.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 22.44 billion
Estimated Year [2025] USD 24.80 billion
Forecast Year [2032] USD 49.46 billion
CAGR (%) 10.38%

A concise orientation to the evolving central nervous system therapeutics landscape emphasizing clinical innovation, patient needs, and commercialization drivers

The central nervous system therapeutics domain is at a pivotal juncture, shaped by converging scientific advances, evolving regulatory expectations, and shifting patterns of care delivery. This executive summary provides a focused orientation to the broad set of therapeutic classes, dosage formats, patient populations, mechanisms of action, and distribution pathways that define contemporary CNS drug development and commercialization. By clarifying how these elements interact, readers can better understand where clinical innovation aligns with unmet needs, and where operational or policy-driven constraints require proactive mitigation.

Across the spectrum from analgesics and antidepressants to antiepileptics and antipsychotics, development strategies increasingly prioritize precision, tolerability, and long-term safety. New formulations and delivery technologies seek to improve adherence and reduce systemic adverse effects, while digital health adjuncts are positioning themselves as complementary solutions for symptom tracking and behavioral interventions. Concurrently, payer expectations and real-world evidence requirements are raising the bar for demonstrating comparative effectiveness and value, influencing both clinical development plans and commercialization timelines.

The central nervous system area demands an integrated view that spans scientific mechanism, patient segmentation, and channel dynamics. This introduction sets the stage for a deeper analysis of the structural shifts reshaping the landscape, the policy changes that are altering cost and supply considerations, and the segmentation insights that inform targeted product and market strategies.

How converging advances in neuroscience, delivery technologies, and care models are reshaping development, access, and lifecycle strategies in CNS therapeutics

Transformative shifts in the central nervous system field are being driven by convergent trends across science, technology, and health systems. Advances in molecular neuroscience and an improved understanding of synaptic and neurotransmitter pathways have created novel targets for modulation, prompting new classes of investigational agents and mechanistic refinements of existing therapies. Precision approaches-rooted in biomarker development and stratified trial designs-are enabling more targeted interventions for heterogeneous conditions, and this, in turn, is reshaping clinical development strategies and regulatory engagement.

Parallel to scientific innovation, delivery science and formulation engineering are altering routes to patient access. Extended-release platforms, novel transdermal systems, and parenteral formats designed for sustained delivery are being prioritized to improve adherence and to differentiate products in crowded therapeutic categories. Digital therapeutics and connected adherence tools are increasingly integrated with drug development programs to demonstrate patient-centric outcomes and to support reimbursement discussions. These adjuncts also create opportunities for lifecycle management and new revenue models that extend beyond traditional pharmaceutical sales.

Health system evolution is redefining commercialization channels. Telemedicine expansion, remote monitoring, and pharmacy delivery models are changing how patients obtain CNS therapies and how clinicians manage long-term conditions. At the same time, regulatory frameworks and payer expectations for real-world evidence are encouraging manufacturers to plan post-authorization evidence generation earlier in development. The combined effect of these shifts is a landscape in which scientific novelty, delivery innovation, and evidence generation must be orchestrated to succeed commercially and clinically.

Understanding the multifaceted influence of evolving U.S. tariffs on supply chain resilience, manufacturing choices, and channel economics for CNS therapeutics

Recent tariff policies originating from the United States have exerted multi-dimensional pressure on CNS drug supply chains, manufacturing economics, and strategic sourcing decisions. Companies that rely on international suppliers for active pharmaceutical ingredients, excipients, or finished dosage forms have needed to reassess vendor portfolios and to increase visibility into tiered supply relationships to maintain continuity of supply. This recalibration often elevates the importance of geographic diversification and of dual sourcing arrangements that can absorb policy-induced cost and logistical shocks.

Tariff-driven cost increases affect different segments of the CNS value chain in distinct ways. Innovator companies with differentiated therapeutic offerings may be better positioned to negotiate price adjustments or to absorb marginal cost increases through value arguments, whereas generic manufacturers operating in thin-margin categories face heightened pressure to optimize production efficiency and to secure low-cost raw materials. Deliberations around onshoring certain manufacturing activities or expanding regional production capacity are now routine elements of portfolio planning conversations, especially for dosage forms that demand complex manufacturing capabilities such as extended-release oral solids or specialized injectable solutions.

In response to tariff-related disruptions, commercial teams have also scrutinized distribution strategies. Shifts in channel economics can influence decisions about the balance between hospital pharmacies, retail pharmacy networks, and online pharmacy partnerships. Moreover, regulatory and payer landscapes can compound tariff effects by influencing reimbursement dynamics and procurement sourcing policies. The net result is a heightened emphasis on scenario planning, clearer contractual protections with suppliers, and more robust supply chain governance to protect both continuity of care and commercial viability.

Deep segmentation-driven insights across drug class, formulation, patient cohort, mechanism, therapeutic area, channel, prescription status, and sales model for precise strategic alignment

A granular view of segmentation reveals differentiated opportunities and operational priorities across product, patient, mechanism, therapeutic area, channel, prescription status, and sales model dimensions. Within drug classes, the market spans analgesic, antidepressant, antiepileptic, antipsychotic, anxiolytic, CNS stimulant, and hypnotic and sedative categories. The analgesic category further divides into non-opioid and opioid analgesics, each with distinct clinical considerations and regulatory scrutiny. Antiepileptic agents cluster by mechanism into calcium channel blockers, GABA enhancers, glutamate inhibitors, and sodium channel blockers, which informs both preclinical modeling and clinical endpoint selection. Antipsychotic compounds bifurcate into atypical and typical classes, while anxiolytics are differentiated into benzodiazepine and non-benzodiazepine treatments. CNS stimulants are characterized by amphetamines and methylphenidate variants, and hypnotic and sedative modalities include barbiturates, benzodiazepines, and non-benzodiazepine hypnotics. Understanding these class-level distinctions is critical for clinical positioning and regulatory risk assessment.

Dosage form segmentation spans capsule, injectable solution, oral solution, tablet, and transdermal patch presentations. Capsules may be standard or extended-release, and injectable solutions may be administered intramuscularly, intravenously, or subcutaneously, each route carrying unique clinical use cases and supply chain implications. Oral solutions are typically provided as suspensions or syrups, whereas tablets can be formulated as delayed-release, extended-release, or standard immediate-release types. Transdermal patches are engineered as matrix or reservoir systems, and they represent an important route for improving adherence and steady-state exposure in select indications. These dosage characteristics influence development complexity, regulatory dossiers, manufacturing investments, and commercial messaging.

Patient type segmentation identifies adult, geriatric, and pediatric populations, underscoring the need for age-appropriate formulations, dosing strategies, and safety monitoring. Mechanism of action segmentation highlights cholinergic, dopaminergic, GABAergic, glutamatergic, noradrenergic, and serotonergic approaches, providing a framework for biomarker selection and for therapeutic differentiation. Therapeutic area segmentation includes ADHD, Alzheimer's disease, anxiety, depression, epilepsy, insomnia, migraine, pain, Parkinson's disease, and schizophrenia; each area brings distinct endpoints, comorbidity profiles, and stakeholder expectations that shape both clinical development and market access pathways. Distribution channel segmentation-hospital pharmacy, online pharmacy, and retail pharmacy-affects fulfillment strategies, patient support programs, and reimbursement alignment. Prescription type segmentation differentiates over-the-counter from prescription products, which has implications for regulatory classification and consumer marketing. Sales model segmentation separates branded from generic offerings, determining the intensity of promotional activity, pricing flexibility, and lifecycle extension tactics. Together, these segmentation lenses create a matrix that decision-makers can use to align R&D priorities, manufacturing investments, and commercial tactics with distinct patient and market needs.

Regional strategic differences across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy, manufacturing location, and market access pathways

Regional dynamics materially influence clinical priorities, regulatory engagement, manufacturing strategy, and commercial execution. In the Americas, the market environment is shaped by payer-driven outcomes expectations, a mature clinical trial ecosystem, and a complex reimbursement architecture that privileges demonstrable real-world effectiveness. Clinical development tends to emphasize comparative effectiveness endpoints and long-term safety data, while commercial strategies often concentrate on managed care negotiations, specialty pharmacy partnerships, and physician network engagement to secure formulary placement.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous procurement systems create a mosaic of access considerations. Countries within this wider region exhibit varying degrees of centralized assessment versus decentralized procurement, and manufacturers need differentiated market access dossiers to address national HTA processes and local pricing negotiations. In addition, regional manufacturing hubs and strategic partnerships with contract manufacturers can be instrumental for market entry and for managing cross-border supply chain risks. Clinical development plans often incorporate multi-jurisdictional requirements early to streamline approvals and reimbursement discussions.

In Asia-Pacific, strong growth in clinical trial activity, rising investment in biomanufacturing, and increasing digital health adoption are notable. Local regulatory authorities are enhancing capabilities and streamlining pathways for innovative therapies, and governments are investing in domestic production capacity for critical therapeutics. Distribution channel innovation-especially rapid expansion of online pharmacy models and telehealth services-shapes access pathways for chronic CNS conditions. Together, these regional characteristics should inform manufacturing location decisions, regulatory engagement sequencing, and tailored commercial models that reflect payers, prescribers, and patient behavior in each geography.

Strategic playbooks and collaborative approaches adopted by innovators, specialty biotechs, generics, and manufacturing partners to gain competitive advantage in CNS therapies

Key companies operating in the central nervous system space demonstrate a range of strategic postures that reflect their pipeline maturity, commercial portfolio composition, and operational strengths. Innovator firms emphasize differentiated mechanisms of action and novel delivery platforms to establish clinical differentiation, while also investing in real-world evidence programs and patient support services to substantiate value propositions. Specialty biotechs often focus on narrow indications with high unmet need and may pursue partnerships or licensing to accelerate late-stage development and commercialization.

Generic and contract manufacturing organizations are concentrating on scale, cost optimization, and flexible manufacturing capabilities to meet demand for established formulation types and to support rapid fill-and-finish needs. These players also explore opportunities to manufacture complex modified-release products and transdermal systems as a route to capture higher-value manufacturing contracts. At the intersection of therapeutic and technology innovation, digital health companies and platform providers are collaborating with pharmaceutical firms to integrate adherence tracking, remote monitoring, and outcome measurement into product value chains, facilitating new evidence generation pathways that support reimbursement dialogues.

Across company types, effective strategies include targeted alliance formation with academic centers and clinical networks to access specialized patient populations, early engagement with regulatory authorities to clarify evidentiary expectations, and disciplined lifecycle management to extend product relevance through formulation improvements or label expansions. Firms that align R&D priorities with pragmatic commercial execution plans and robust supply chain governance are best positioned to navigate the complexity of CNS markets.

Practical strategic imperatives for leaders to bolster supply chain resilience, align formulation innovation with payer evidence, and accelerate market access in CNS therapeutics

Industry leaders should pursue a set of actionable priorities that balance scientific ambition with operational pragmatism and market realism. First, strengthen supply chain resilience by diversifying supplier relationships and incorporating dual sourcing for critical active ingredients and complex excipients. Scenario-based procurement planning and contractual protections can mitigate policy-driven disruptions and reduce the risk of service interruptions for patients.

Second, invest strategically in dosage form innovation that aligns with adherence and safety imperatives. Extended-release formulations, transdermal systems, and patient-friendly oral solutions can differentiate products in competitive categories and support improved clinical outcomes. Product teams should align these formulation choices with payer evidence needs and with pragmatic manufacturing pathways that control complexity and time to market.

Third, design development programs that integrate real-world evidence generation from the outset. Early planning for pragmatic trials, registry-based outcome collection, and post-authorization safety studies can accelerate reimbursement discussions and strengthen clinical value claims. Fourth, prioritize targeted market access strategies by engaging payers and health technology assessment bodies early to understand evidence thresholds and to co-design outcome measures that matter for coverage decisions.

Fifth, pursue partnerships across the ecosystem-including academic centers, digital health firms, and experienced contract development organizations-to fill capability gaps and to accelerate time-to-market. Finally, execute a differentiated commercial strategy that tailors messaging and channel mix to patient segments and provider workflows, leveraging specialty pharmacy capabilities where appropriate and embracing online pharmacy channels to meet evolving patient preferences.

Methodological overview combining primary expert interviews, systematic secondary synthesis, and scenario-driven analysis to ensure reproducible and actionable CNS market insights

The research methodology behind this analysis combines structured primary inquiry with comprehensive secondary synthesis to produce robust, triangulated insights. Primary research activities included in-depth interviews with clinical experts, regulatory specialists, supply chain managers, and commercial leaders involved in central nervous system drug development and distribution. These conversations provided qualitative context around clinical priorities, evidentiary expectations, and operational constraints that inform strategic decision-making.

Secondary research involved systematic review of peer-reviewed literature, clinical trial registries, regulatory guidance, public company disclosures, and industry conference materials. Data were cross-validated across multiple public and proprietary sources to reduce bias and to ensure consistency of interpretation. The study also integrated case-based analyses of recent product launches and regulatory interactions to surface practical lessons that are relevant across therapeutic classes and dosage forms.

Analytic techniques included thematic synthesis to identify cross-cutting trends, scenario planning to explore the implications of policy and supply chain shifts, and gap analysis to expose unmet clinical and commercial needs. Quality control measures included peer review by subject matter experts and reconciliation of divergent perspectives through iterative validation. The methodology emphasizes transparency, reproducibility, and pragmatic interpretation so that findings can be directly applied to portfolio planning, due diligence, and market entry strategy.

Synthesis of strategic imperatives emphasizing integrated clinical differentiation, operational resilience, and payer-aligned evidence generation to secure durable CNS market access

The combined insights from scientific advances, formulation innovation, regulatory evolution, and distribution transformation point to a central theme: success in the central nervous system therapeutics domain requires integrated strategy that aligns clinical differentiation with operational excellence. Companies that can translate mechanistic novelty into patient-relevant outcomes while ensuring supply continuity and payer alignment stand to create sustainable value. Conversely, firms that underestimate the operational or evidence-generation demands of contemporary payers and providers may face access barriers despite clinical promise.

Strategic clarity-rooted in segmentation-driven planning, regional nuance, and a rigorous appreciation of supply chain and policy dynamics-enables stakeholders to prioritize investments and to design partnerships that accelerate clinical and commercial milestones. The recommendations in this summary are intended to guide deliberative action: fortify supply networks, select formulation and delivery modalities that improve adherence and differentiate products, engage payers and regulators early, and integrate real-world evidence into commercialization plans. By adopting these practices, teams can better navigate the complexity of CNS markets and position novel and established therapies for durable clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of digital therapeutics integrating AI for personalized depression management
  • 5.2. Accelerated FDA approvals of novel neuroprotective agents for Alzheimer's disease progression
  • 5.3. Expansion of pipeline of novel psychedelic-based treatments for treatment resistant psychiatric disorders
  • 5.4. Increased investment in precision medicine biomarkers to predict efficacy of epilepsy therapies
  • 5.5. Emergence of long acting implantable devices for sustained antipsychotic drug delivery in schizophrenia
  • 5.6. Growing collaboration between biotech and academic institutions to accelerate CNS drug discovery and development
  • 5.7. Integration of real world data and wearables for monitoring treatment outcomes in multiple sclerosis management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Drugs Market, by Drug Class

  • 8.1. Analgesic
    • 8.1.1. Non-Opioid Analgesic
    • 8.1.2. Opioid Analgesic
  • 8.2. Antidepressant
  • 8.3. Antiepileptic
    • 8.3.1. Calcium Channel Blocker
    • 8.3.2. Gaba Enhancer
    • 8.3.3. Glutamate Inhibitor
    • 8.3.4. Sodium Channel Blocker
  • 8.4. Antipsychotic
    • 8.4.1. Atypical
    • 8.4.2. Typical
  • 8.5. Anxiolytic
    • 8.5.1. Benzodiazepine
    • 8.5.2. Non-Benzodiazepine
  • 8.6. Cns Stimulant
    • 8.6.1. Amphetamines
    • 8.6.2. Methylphenidate
  • 8.7. Hypnotic And Sedative
    • 8.7.1. Barbiturates
    • 8.7.2. Benzodiazepine
    • 8.7.3. Non-Benzodiazepine Hypnotics

9. Central Nervous System Drugs Market, by Dosage Form

  • 9.1. Capsule
    • 9.1.1. Extended-Release Capsule
    • 9.1.2. Standard Capsule
  • 9.2. Injectable Solution
    • 9.2.1. Im
    • 9.2.2. Iv
    • 9.2.3. Subcutaneous
  • 9.3. Oral Solution
    • 9.3.1. Suspension
    • 9.3.2. Syrup
  • 9.4. Tablet
    • 9.4.1. Delayed-Release Tablet
    • 9.4.2. Extended-Release Tablet
    • 9.4.3. Standard Tablet
  • 9.5. Transdermal Patch
    • 9.5.1. Matrix Patch
    • 9.5.2. Reservoir Patch

10. Central Nervous System Drugs Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Central Nervous System Drugs Market, by Mechanism Of Action

  • 11.1. Cholinergic
  • 11.2. Dopaminergic
  • 11.3. Gabaergic
  • 11.4. Glutamatergic
  • 11.5. Noradrenergic
  • 11.6. Serotonergic

12. Central Nervous System Drugs Market, by Therapeutic Area

  • 12.1. ADHD
  • 12.2. Alzheimer's Disease
  • 12.3. Anxiety
  • 12.4. Depression
  • 12.5. Epilepsy
  • 12.6. Insomnia
  • 12.7. Migraine
  • 12.8. Pain
  • 12.9. Parkinson's Disease
  • 12.10. Schizophrenia

13. Central Nervous System Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Central Nervous System Drugs Market, by Prescription Type

  • 14.1. Over The Counter
  • 14.2. Prescription

15. Central Nervous System Drugs Market, by Sales Model

  • 15.1. Branded
  • 15.2. Generic

16. Central Nervous System Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Central Nervous System Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Central Nervous System Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Roche Holding AG
    • 19.3.2. Biogen Inc.
    • 19.3.3. Novartis AG
    • 19.3.4. Johnson & Johnson
    • 19.3.5. Otsuka Pharmaceutical Co., Ltd.
    • 19.3.6. Eli Lilly and Company
    • 19.3.7. Teva Pharmaceutical Industries Ltd.
    • 19.3.8. H. Lundbeck A/S
    • 19.3.9. Pfizer Inc.
    • 19.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY R